Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Side Branch Treatment in Bifurcation Lesions: Are Drug-Coated Balloons Better?

Courtesy of Dr. Juan Manuel Pérez.

Bifurcation lesions account for up to 20% of all coronary angioplasties. The most commonly used strategy is provisional stenting of the main vessel, with optional side branch treatment. Given the ongoing debate over the optimal management of a compromised side branch, this meta-analysis compared the clinical efficacy of drug-eluting balloons (DEBs) versus non-coated balloons (NCBs) in these cases.

Researchers included five studies (two randomized clinical trials and three observational studies), with a total of 1762 patients. The average population age ranged between 60 and 70 years, with a predominance of men (73–83%). Most patients presented with acute coronary syndrome (56–91%) and between 4% and 28% experienced chronic coronary syndrome. The lesions were mostly true bifurcations (Medina 1,1,1), predominantly located in the left anterior descending artery and the circumflex artery. The treated side branches had diameters between 2.0 and 2.5 mm, and the drug-eluting balloons used were mainly coated with paclitaxel.

The pooled analysis showed that the use of DEBs was associated with a reduction of almost 50% in the likelihood of experiencing a major adverse cardiovascular event (MACE) (odds ratio [OR] 0.48; p <0.0001), as well as a 61-% reduction in the rate of acute myocardial infarction (AMI) (OR 0.39; p <0.001).

Read also: Decompensated Aortic Stenosis: Time to TAVR Matters.

Regarding the need for repeat intervention, the use of DEBs was associated with a 38-% reduction in the likelihood of requiring a new side branch revascularization (target lesion revascularization, TLR) and a 74-% reduction in target vessel revascularization (TVR, which includes both the main vessel and the side branch). However, while there was a favorable trend with DEB use, none of these differences reached statistical significance.

Conclusion

In bifurcation lesions treated with provisional stenting, the use of DEBs in the side branch is associated with a significant reduction in MACE and AMI compared to the use of conventional balloon. While there were no statistically significant differences in reintervention rates (TLR or TVR), there was an obvious trend towards DEB use. These results support its use as an effective alternative to conventional balloons, particularly in single-stent strategies.

Original Tile: Drug‐Coated Balloons Versus Non‐Coated Balloons for Side Branch Treatment in Bifurcation Lesions: A Systematic Review and Meta‐Analysis.

Reference: Rocchetti M., Tua L., Cereda A., Conconi B., Franchina AG, Carlà M., Spangaro A., Lucreziotti S. Cardiovascular Catheter Interv. 2025;1–10. doi:10.1002/ccd.3157.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...